Currently out of the existing stock ratings of Michael Ryskin, 31 are a HOLD (36.47%), 40 are a BUY (47.06%), 14 are a SELL (16.47%).

Michael Ryskin

Work Performance Price Targets & Ratings Chart

Analyst Michael Ryskin, currently employed at BAML, carries an average stock price target met ratio of 56.19% that have a potential upside of 12.79% achieved within 111 days.

Michael Ryskin’s has documented 163 price targets and ratings displayed on 21 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on RXRX, Recursion Pharmaceuticals at 26-Feb-2026.

Wall Street Analyst Michael Ryskin

Analyst best performing recommendations are on OMIC (SINGULAR GENOMICS SYSTEMS).
The best stock recommendation documented was for OMIC (SINGULAR GENOMICS SYSTEMS) at 6/21/2021. The price target of $780 was fulfilled within 3 days with a profit of $85.2 (12.26%) receiving and performance score of 40.88.

Average potential price target upside

of $48.21 (11.46%) on IDXX (IDEXX LABORATORIES).
of $22.57 (15.6%) on ZTS (ZOETIS).
of $18.01 (7.29%) on DHR (DANAHER).

ABSI Absci Corp ALGN Align Technology ELAN Elanco Animal Health IDXX IDEXX Laboratories OMIC Singular Genomics Systems SDC SmileDirectClub SDGR Schrodinger RXRX Recursion Pharmaceuticals EXAI Exscientia Ltd ADR ZTS Zoetis MRVI Maravai Lifesciences Holdings ILMN Illumina AVTR Avantor CERT Certara DHR Danaher TEM Tempus AI, Common Stock BRKR Bruker CRL Charles River Laboratories ICLR ICON PLC MTD Mettler-Toledo International PAHC Phibro Animal Health

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gil Blum (NEEDHAM)